TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38690606
Drug: Prednisolone 5
Normalized name: prednisolone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 5 mg daily
Study: 35260464
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg two times a day)
Study: 35260464
Drug: Low-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity warfarin (INR target 1.7-2.2)
Study: 35260464
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg/day)
Study: 34823375
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment (exact dosage and duration not specified)
Study: 38236314
Drug: Eptinezumab 100
Normalized name: EPTINEZUMAB 100 mg in 1 mL INTRAVENOUS INJECTION [Vyepti]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptinezumab 100 mg
Study: 33023473
Drug: Eptinezumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptinezumab (both doses)
Study: 34038904
Drug: Snail Soothing
Normalized name: Snail, unspecified
DrugBank: Snail, unspecified (DB14245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snail Soothing and Repairing (SSR) cream applied twice daily for 14 days
Study: 34038904
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice daily for 14 days
Study: 36484185
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (drugs, catheterization, bladder function rehabilitation training)
Study: 34263648
Drug: Saffron total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron total glycoside tablets (four tablets each time, three times each day for 6 months)
Study: 34263648
Drug: Placebo (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (four tablets each time, three times each day for 6 months)
Study: 34263648
Drug: Saffron total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron total glycoside tablets
Study: 33010240
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide 25 mg and emtricitabine 200 mg, and dolutegravir 50 mg
Study: 33010240
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg, and dolutegravir 50 mg
Study: 33010240
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and efavirenz 600 mg
Study: 36209235
Drug: WGS-guided automated
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WGS-guided automated treatment recommendation strategy for individualized treatment of RR-TB
Study: 36209235
Drug: RR-TB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RR-TB treatment according to the national South African guidelines
Study: 32880493
Drug: Pulsed Radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Radiofrequency (PRF) in addition to Transforaminal Epidural Steroid Injection (TFESI)
Study: 32880493
Drug: Transforaminal Epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal Epidural Steroid Injection (TFESI) alone
Study: 35147583
Drug: Participants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with viral load >400 copies/mL
Study: 32410827
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of autologous bone marrow-derived lineage-negative stem/progenitor cells (LIN- SPCs)
Study: 33534266
Drug: Continuous renal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous renal replacement therapy
Study: 35632653
Drug: GamCOVIDVac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GamCOVIDVac vaccine
Study: 35632653
Drug: EpiVacCorona vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EpiVacCorona vaccine
Study: 35632653
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific vaccine (prior to vaccination)
Study: 36394933
Drug: Kombucha drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kombucha drink (KG), 220 ml, enriched with inulin (1.15 g/100 ml) for 10 days
Study: 36394933
Drug: Water (Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (Control Group, CG), 220 ml for 10 days
Study: 34587911
Drug: Beta-lactam antibiotics
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam antibiotics plus fluoroquinolones
Study: 34587911
Drug: Beta-lactam antibiotics
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam antibiotics alone
Study: 34571050
Drug: Rifaximin‐α (550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin‐α (550 mg BID)
Study: 34538257
Drug: Ixekizumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab (80 mg every 2 weeks or every 4 weeks)
Study: 32703583
Drug: Initial intravenous
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial intravenous bolus of low-dose heparin (40 IU/kg)
Study: 38942047
Drug: Namilumab 150
Normalized name: sarilumab
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Namilumab 150 mg
Study: 32203971
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-specific treatment component)
Study: 33320777
Drug: High-fructose corn
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fructose corn syrup
Study: 35761841
Drug: PDL1/PD-1 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDL1/PD-1 inhibitors
Study: 33478890
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of life (measured by Functional Assessment of Chronic Illness Therapy – Palliative Care)
Study: 32327669
Drug: Micro-dosing application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-dosing application of 30.75 kg N ha-1 and 34.5 kg P2O5 ha-1 (N applied in three splits: 1/3 at sowing, 1/3 at emergence, and 1/3 at 45 days after emergence) at Aybra.
Study: 32327669
Drug: Micro-dosing application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-dosing application of 20.5 kg N ha-1 and 23 kg P2O5 ha-1 (N applied in three splits: 1/3 at sowing, 1/3 at emergence, and 1/3 at 45 days after emergence) at Shumshiha-Lasta Lalibela.
Study: 34417673
Drug: Anti-beta-1-adrenergic receptor
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-beta-1-adrenergic receptor antibodies (anti-β1-AR) in patients with CCM
Study: 33218873
Drug: Brain Endurance
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain Endurance Training (BET) group completed concurrent cognitive tasks (2-back, Stroop) during 24 submaximal hand contractions sessions over 6 weeks.
Study: 33218873
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group completed 24 submaximal hand contractions sessions over 6 weeks without concurrent cognitive tasks.
Study: 33310604
Drug: Meditation program
Normalized name: Meditize
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meditation program involving daily use of the 'Muse' device for eight weeks
Study: 35260292
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) by telephone
Study: 32103319
Drug: Two whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two whole apples daily for 8 weeks
Study: 34558768
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 or 25 mg)
Study: 34240673
Drug: Menopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Menopausal hormone therapy (MHT) - estradiol gel (1.5 mg/day) + oral micronized progesterone (100 mg/day)
Study: 32434932
Drug: Ecologic Femi+
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ecologic Femi+ (EF+) vaginal capsule
Study: 32434932
Drug: Gynophilus LP
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynophilus LP (GynLP) vaginal tablet
Study: 35105307
Drug: Topical local
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical local anesthesia with EMLA®
Study: 35105307
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water injections without topical local anesthesia (Control group 1)
Study: 35105307
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline 0.9% with topical local anesthesia (Control group 2)
Study: 35105307
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline 0.9% without topical local anesthesia (Control group 3)
Study: 33121861
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (preferred genre played during treatment)
Study: 35125224
Drug: MAS-1 adjuvanted
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAS-1 adjuvanted IIV (0.3 mL, 9 µg per HA)
Study: 35125224
Drug: MAS-1 adjuvanted
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAS-1 adjuvanted IIV (0.5 mL, 9 µg per HA)
Study: 35125224
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose IIV (Fluzone HD, 60 µg per HA)
Study: 34237655
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (SMO) 0.75, 1.25, 1.75 or 2.25 g t.i.d. for 12 weeks
Study: 33799341
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment of the first dorsal interosseous muscle trigger points (MTrPs)
Study: 34867113
Drug: Routine radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine radiotherapy and chemotherapy with routine nursing intervention
Study: 32563606
Drug: Bivalent VLP
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent VLP vaccine with MPL
Study: 32563606
Drug: Bivalent VLP
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent VLP vaccine without MPL
Study: 32563606
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one dose)
Study: 32563606
Drug: Bivalent VLP
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent VLP vaccine (one dose)
Study: 32563606
Drug: Bivalent VLP
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent VLP vaccine (two doses)
Study: 35452688
Drug: Oral propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propafenone
Study: 34551681
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention group (oral presentation by CPCC and distribution of gift packages)
Study: 32674126
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 800 mg on day 1 followed by 400 mg once daily for 6 days
Study: 32153050
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine 10% spray
Study: 32153050
Drug: Oral dapoxetine
Normalized name: duloxetine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dapoxetine 60 mg
Study: 34463398
Drug: Laughter therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laughter therapy applied twice a week for 4 weeks
Study: 35830482
Drug: Insulin correlation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin correlation with GIP and RQ
Study: 34479761
Drug: Ketoprofen plaster
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen plaster 30 mg twice daily (n = 118)
Study: 34479761
Drug: Diclofenac plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac plaster 15 mg once daily (n = 118)
Study: 34479761
Drug: Ketoprofen plaster
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen plaster 30 mg twice daily
Study: 34479761
Drug: Diclofenac plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac plaster 15 mg once daily
Study: 34479761
Drug: Frequency of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency of rescue medication use
Study: 34099584
Drug: High-fat load
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat load (150 g of fat at time 0)
Study: 34099584
Drug: High-fat load
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat load with fructose (three doses of 50 g at 0, 2, and 4 hours)
Study: 34099584
Drug: High-fat load
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat load with glucose (three doses of 50 g at 0, 2, and 4 hours)
Study: 32985288
Drug: Urea cream
Normalized name: Amino Acid-Urea Cream
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea cream
Study: 33952245
Drug: Group behavior
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group behavior therapy knowledge, attitude, and beliefs assessment
Study: 33892671
Drug: EPIC program
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPIC program (intervention with peer recovery supporter, family treatment drug court, medications for opioid use disorders, home-based parenting supports)
Study: 33892671
Drug: Comparison groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison groups (Ohio START and treatment as usual)
Study: 34884273
Drug: Scenar-On group
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scenar-On group (active treatment)
Study: 34884273
Drug: Scenar-Off group
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scenar-Off group (sham treatment)
Study: 34658139
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel containing 5% onion extract
Study: 34658139
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel containing vitamin C (Control)
Study: 34037282
Drug: palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: palbociclib (125 mg/day, 3/1 schedule)–fulvestrant (500 mg, intramuscular injection)
Study: 36231171
Drug: Pain Education
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain Education Therapy (PET) group (n = 24)
Study: 35986170
Drug: Traditional dysphagia
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dysphagia therapy (TDT)
Study: 35922794
Drug: Comparator formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator formulation of Ginkgo biloba extract
Study: 32438401
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein (31 g, 26.2 g protein: 2.5 g leucine)
Study: 32438401
Drug: Mycoprotein (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycoprotein (70 g, 31.5 g protein: 2.5 g leucine)
Study: 34137291
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic prophylaxis (no AP)
Study: 34137291
Drug: 2-year antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-year antibiotic prophylaxis (2-y AP)
Study: 34137291
Drug: Lifetime antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifetime antibiotic prophylaxis (lifetime AP)
Study: 34544205
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg once daily for 3 months
Study: 33567400
Drug: Cenobamate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate treatment (100–400 mg/day)
Study: 33567400
Drug: Cenobamate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate treatment (150–400 mg/day)
Study: 33567400
Drug: Cenobamate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate treatment
Study: 34293411
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl 2.5 mcg.mL‐1 (Group 1)
Study: 34293411
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl 5 mcg.mL‐1 (Group 2)
Study: 33058835
Drug: Testosterone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (150 mg)
Study: 36281113
Drug: Low-to moderate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-to moderate intensity aerobic training (30 minutes daily)
Study: 36281113
Drug: Conventional customized
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional customized physiotherapy (60 minutes daily)
Study: 33625653
Drug: Pharmacist interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist interventions for drug-related problems (DRPs)
Study: 33726810
Drug: Personalised hip
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised hip therapy (PHT)
Study: 33726810
Drug: Personalised hip
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised hip therapy (PHT) to Hip arthroscopic surgery (HA)
Study: 35968501
Drug: Sufentanil combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil combined with propofol (0.01‐0.03 μg/(kg·min) of sufentanil + 80‐100 μg/(kg·min) of propofol)
Study: 35968501
Drug: Fentanyl (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (3 μg/(kg·h) of fentanyl + 80‐100 μg/(kg·min) of propofol)
Study: 34548368
Drug: Clarithromycin 800
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 800 mg/day
Study: 34548368
Drug: Clarithromycin 400
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 400 mg/day
Study: 34548368
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without clarithromycin
Study: 34215452
Drug: MenB‐FHbp booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenB‐FHbp booster dose administered 48 months after primary series
Study: 34215452
Drug: MenB‐FHbp booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenB‐FHbp booster dose
Study: 32379374
Drug: Intraderma injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraderma injection of 5-fluorouracil (5-FU)
Study: 32713183
Drug: Prednisolone, 0.5
Normalized name: Moxifloxacin-Prednisolone, 0.5 g-1 g (1 g-1 g dose) ophthalmic suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone, 0.5 mg/kg (maximum dose 20 mg/day) qAM × 3 days postoperatively
Study: 32713183
Drug: Non-steroid group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid group
Study: 33459540
Drug: Modified-release betahistine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release betahistine (48 mg once daily)
Study: 33459540
Drug: Betaserc (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaserc (24 mg twice daily)
Study: 35869533
Drug: Empower-Autism programme
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Empower-Autism programme plus treatment-as-usual
Study: 35869533
Drug: Usual local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual local post-diagnostic offer plus treatment-as-usual
Study: 35482080
Drug: Alemtuzumab treatment
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab treatment
Study: 33266039
Drug: Telephone-based parent
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based parent intervention (4 weekly 30-min support calls)
Study: 36105267
Drug: START Together
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: START Together (experimental treatment)
Study: 34688369
Drug: Mirtazapine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (titrated to 45 mg)
Study: 33875799
Drug: 2.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g/d of omega-3
Study: 33875799
Drug: 1.25 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 g/d of omega-3
Study: 33754455
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing strategies
Study: 32667654
Drug: Rotigotine 2
Normalized name: ROTIGOTINE 2MG/24HRS PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine 2 mg transdermal patch for 1 week followed by a 4 mg patch for 23 weeks
Study: 32667654
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal patch for 24 weeks
Study: 35484309
Drug: Lozenge
Normalized name: LOZENGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge